Brief: Clover Biopharmaceuticals Launches Quadrivalent Seasonal Influenza Vaccine In Mainland China
12/09/2023 02:26
Sept 12 (Reuters) - Clover Biopharmaceuticals Ltd
2197.HK :
* CLOVER LAUNCHES QUADRIVALENT SEASONAL INFLUENZA VACCINE IN
MAINLAND CHINA
* SALES FROM ADIMFLU-S (QIS) ARE EXPECTED TO BE ACCRETIVE TO
COMPANY'S FINANCIALS STARTING IN 2023
Further company coverage: 2197.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune